Euthymics Bioscience Inc.
This article was originally published in Start Up
Executive Summary
There’s nothing new to the notion of combining CNS modulators to create synergistic formulations for treating depression, but tuning the balance has been difficult. Euthymics Bioscience Inc. thinks it has found the right mix. The company’s formula, now in midstage clinical testing, combines serotonin, norepinephrine and dopamine modulators in a way that results in a ratio of 1:2:8. The company plans to test its candidate against paroxetine to show improvement over a generic standard of care. If it succeeds, it could move to the front of the second line of antidepressant agents.